ClinicalTrials.gg
Status unknownNCT02846753Updated Apr 21, 2023

Implantation of the Venus P-Valve™ in the Pulmonic Position in Patients With Native Outflow Tracts

An interventional study of trans catheter heart valve replacement in Pulmonary Regurgitation, sponsored by Venus MedTech (HangZhou) Inc.. Status unknown. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Venus MedTech (HangZhou) Inc. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
12 Years to 70 Years
Sex
All
01

Study summary

A prospective, non-randomized multi-center clinical investigation of the Venus P-Valve™ for the treatment of pulmonary regurgitation with or without stenosis in patient with native outflow tracts.

Read the detailed description

This study evaluates the implantation of the Venus P-Valve™ for the treatment of patients with an incompetent pulmonic valve, which causes blood to flow back from the pulmonary artery into the right heart ventricle during pumping of the heart (pulmonary regurgitation). Patients with and without narrowing (stenosis) of the right ventricular outflow tract will be included. The purpose of this protocol is to assess the safety and performance of Venus P-Valve™ implantation.

Post-procedure, a clinical visit will be scheduled at 30 days, 6 month, 12 months, and annually thereafter to 3 years. Population: Patients≥12 years with a body weight of ≥30kg, with significant pulmonary regurgitation (≥3+) with or without right ventricular outflow tract (RVOT) stenosis (mean Doppler gradient ≥35mmHg) with native right ventricular outflow tracts.

02

Conditions studied

  • Pulmonary Regurgitation
03

In context

Pulmonary Valve Insufficiency

31 studies on the registry are indexed under Pulmonary Valve Insufficiency; 8 are open to participants now.

This study's enrollment of 84 is above the median of 60 across 21 interventional studies indexed under Pulmonary Valve Insufficiency.

Browse Pulmonary Valve Insufficiency studies →

Lead sponsor

Venus MedTech (HangZhou) Inc. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Candidates for this study must meet all of the following Inclusion criteria:

  • Age: range from 12-70 years of age
  • Weight must be "equal to" or exceed 30 kilograms
  • Subject presents with evidence of moderate or severe (≥3+) pulmonary regurgitation by TTE
  • Subject presents with >30% pulmonary regurgitation fraction as defined by cardiac MRI
  • Subject is symptomatic from his/her pulmonary regurgitation or meets MRI criteria for intervention: right ventricular ejection fraction (RVEF) \< 45%, pulmonary regurgitant fraction (PRRF) >30% and increased right ventricular end-diastolic volume (RVEDV) >150ml/m2
  • Subject will comply with specified follow-up evaluations, including echocardiograms and MRI
  • The subject or the subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written as approved by the ethics committee and regulatory authority if applicable of the respective clinical site
  • The subject and the treating physician agree that the subject will return for all required post-procedure follow up visits
  • Catheterization is determined to be feasible by the treating physician

Exclusion criteria

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are present:

  • Active infection requiring current antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics)
  • Severe chest wall deformity
  • Leukopenia (WBC\<3000 mm3)
  • Acute or chronic anemia ( \<90g/l)
  • count \<100,000 cells/mm3
  • In the judgment of the investigator, percutaneous introduction and delivery of the valve is not feasible
  • Need for emergency cardiac or vascular surgery, including pulmonary embolectomy, for any reason
  • Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
  • History of, or active, endocarditis, unless the endocarditis has been treated >6 months previous to the procedure
  • History of or current intravenous drug abuse
  • A known to aspirin or heparin
  • Currently participating in an drug or another device study [Note: Trials requiring extended follow up for products that were investigational, but have since become commercially available, are not considered investigational devices.]
  • Major or progressive non-cardiac disease resulting in a of \<1yr
  • Obstruction of the central veins preventing advancement of the pulmonary bioprosthesis delivery system to the heart
  • Positive urine or serum pregnancy test in female subjects of
  • Ileofemoral vessel characteristics that would preclude safe placement of 19 French (F), 22 F and 24 F introducer sheath
  • for cardiac magnetic resonance imaging or inability to cooperate with a cardiac magnetic resonance imaging exam
  • Need for concomitant interventional procedures
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Implantation of Venus P-Valve™

    Implantation of the Venus P-Valve™ in the pulmonic position in patients with native outflow tracts; trans catheter heart valve replacement.

    Procedure: trans catheter heart valve replacement

Interventions

  • Proceduretrans catheter heart valve replacement

    trans catheter heart valve replacement

06

What researchers measure

Primary outcomes

  1. Safety of Venus P-Valve™ measured as probability of death/reoperation

    Occurrence of death or reoperation (Valve and/or procedure related) calculated as a composite freedom-of-death and -reoperation probability at 12 months. The acceptance criterion for mortality and reoperation is 16% (or equivalently 84% freedom from death and reoperation). If the lower 95% confidence limit for survival and freedom from reoperation at 12 months is greater than 84%, the acceptance criterion for safety will have been met.

    Time frame: month 12 follow-up

  2. Safety of Venus P-Valve™ measured as probability of Major Adverse Cardiac and Cerebro-vascular Event (MACCE)

    Occurrence of MACCE (defined as death, myocardial infarction, reoperation, vascular injury resulting in the need for an unplanned vascular grafting intervention, stroke, and pulmonary embolism) calculated as freedom-from-MACCE probability at month-1, calculated using the Kaplan Meier method

    Time frame: month 1 follow-up

  3. Performance of Venus P-Valve™ measured as Success rate of valve placement and implantation

    The device success is defined as the percentage of subjects with successful implant of the P-Valve assessed at the earliest evaluable echocardiogram. Linearized rates will be presented.

    Time frame: up to 30 days

  4. Hemodynamic Performance of Venus P-Valve™ measured as the mean transvalvular pressure (mmHg)

    Hemodynamic performance, measured as the mean transvalvular pressure gradient measured by transthoracic echocardiogram at month-1

    Time frame: 1 month

  5. Performance of Venus P-Valve™ measured as change of pulmonary regurgitation (regurgitation classification by MRI)

    Improvement or abolition of pulmonary regurgitation assessed by MRI at baseline and month 6, with grading of pulmonary stenosis defined as: mild \<2, moderate: 2-4; severe \>4

    Time frame: baseline and month 6

  6. Performance of Venus P-Valve™ measured as change of pulmonary regurgitation (regurgitation classification by transthoracic echocardiogram)

    Improvement or abolition of pulmonary regurgitation assessed by transthoracic echocardiogram at baseline, day 1, month 1, 6, 12 and annually thereafter to 3 years post procedure, with grading of pulmonary stenosis defined as: mild \<2, moderate: 2-4; severe \>4

    Time frame: baseline, day 1, month 1, 6, 12 and annually thereafter to 3 years post procedure

  7. Performance of Venus P-Valve™ measured as percentage of subjects with structural valve deterioration

    Structural valve deterioration assessment includes stent fracture, leaflet mobility, thickening and calcification

    Time frame: month 6

Secondary outcomes

  1. Safety measured as percentage of subjects experiencing serious adverse events

    Within the duration of the study of the percentage of patients experiencing the following events is measured: * Device migration/embolization * Valvar thrombosis * Thromboembolism * Bleeding * Paravalvar leak * Endocarditis * Nonstructural dysfunction * Explant * Hemolysis * Arrhythmias * all other serious adverse events as defined in protocol section 6.2

    Time frame: up to third year of follow-up

  2. Functional improvement measured as decreased pulmonary regurgitation (regurgitation classification by transthoracic echocardiogram )

    Improved valve function demonstrated by a decrease in pulmonary regurgitation (PR) to mild or less (≤ 2) by transthoracic echocardiogram (TTE) at month-1

    Time frame: 1 month

  3. Functional improvement measured as decreased pulmonary regurgitation (regurgitation classification by MRI)

    Improved valve function demonstrated by a decrease in pulmonary regurgitation (PR) to mild or less (≤ 2) by MRI at month-6

    Time frame: month 6

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — The results of the study will be reported and disseminated in peer-reviewed scientific journals, internal reports, conference presentations and submissions to regulatory authorities. Nevertheless, all data used in the analysis and reporting of this clinical investigation will be without identifiable reference to individual patients. All the data will be anonymous.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Jul 2022, 71 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2016
First posted
Jul 27, 2016
StartActual
Aug 17, 2016
Primary completionActual
Jul 31, 2022
CompletionEst.
Dec 31, 2024
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02846753
Lead sponsor
Venus MedTech (HangZhou) Inc.
Collaborators
IQVIA Inc., TheraGenesis, Intrials
Responsible party
Sponsor
First posted
Jul 27, 2016
Start date
Aug 17, 2016
Primary completion
Jul 31, 2022
Completion
Dec 31, 2024 (estimated)
Last update
Apr 21, 2023

Study contacts

Shakeel A. Qureshi, MD
principal investigator · Evelina Children's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion